Herpes Labialis Clinical Trial
Official title:
Study to Evaluate the Safety and Performance of Compeed® Cold Sore Patch Night in the Treatment of Herpes Labialis
The primary objective of this study was to evaluate the safety and performance of a cold sore patch for the treatment of herpes labialis.
This was an open, single-center multi-site, non-comparative study to evaluate the safety and performance of CSP-Night under actual-use conditions in subjects with herpes labialis of the lips and/or perioral skin. A sufficient number of subjects were screened to ensure that 45 subjects experienced and treated a cold sore outbreak in the course of 14 weeks. Subjects were instructed to initiate therapy within approximately 1 hour of onset of their first sign or symptom. Treatment was continued until the lesion healed, or for a maximum of 10 days. All subjects were expected to return to the study center for clinical assessments within 24 hours and 48 hours after initiating treatment, and every other day thereafter, with a final visit at Day 10 or at the time of completion/discontinuation if before Day 10. Diaries were completed each day, beginning upon initiation of therapy and continuing until study completion/ discontinuation, and included information on study product applications and compliance. ;
Intervention Model: Single Group Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02483182 -
Safety, Tolerability and Therapeutic Efficacy of Topical ZEP-3 Ointment (1.0%) for the Treatment of Cold Sores
|
Phase 2 | |
Completed |
NCT00297011 -
Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis
|
Phase 2 | |
Completed |
NCT03310294 -
Immune Evidence to the Consumption of Lactobacillus GG and FOS Consumption in Patients With Herpes Labialis
|
N/A | |
Terminated |
NCT04539483 -
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection
|
Phase 2 | |
Completed |
NCT02265913 -
Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
|
Phase 3 | |
Completed |
NCT01971385 -
Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis
|
Phase 1 | |
Active, not recruiting |
NCT01695187 -
NB-001 Treatment of Recurrent Herpes Labialis
|
Phase 3 | |
Completed |
NCT00375570 -
Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents
|
Phase 3 | |
Completed |
NCT02871492 -
Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
|
Phase 2 | |
Completed |
NCT01484067 -
Study of a Cold Sore Patch for the Treatment of Herpes Labialis
|
N/A | |
Completed |
NCT00769314 -
Phase 3 Clinical Study for the Treatment of Cold Sore
|
Phase 3 | |
Completed |
NCT00878072 -
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis
|
Phase 2/Phase 3 | |
Completed |
NCT01574612 -
Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
|
Phase 3 | |
Completed |
NCT03661541 -
Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)
|
Phase 1 | |
Recruiting |
NCT01306084 -
Viral Infections in Healthy and Immunocompromised Hosts
|
||
Terminated |
NCT03521479 -
A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis
|
Phase 2 | |
Terminated |
NCT00913692 -
A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis
|
Phase 2 | |
Completed |
NCT02207881 -
A Double-Blind, Randomized, Placebo-Controlled Study of Topical VDO for the Treatment of Herpes Simplex Labialis
|
Phase 2 | |
Completed |
NCT01653509 -
An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode
|
Phase 1 | |
Completed |
NCT00361881 -
Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis
|
Phase 3 |